Latest studies
- Active not recruitingPHASE3
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
This study is looking at a new medicine called Olezarsen for people with very high triglyceride levels. It's an ongoing study for those who have already started the treatment in previous trials, checking its long-term safety and how well it's tolerated.
Severe HypertriglyceridemiaMalaysia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
This study looks at a new drug, claseprubart, for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see if the drug helps people with CIDP and if it's safe. Some participants will receive the drug, and others a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyMalaysia - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaMalaysia - Active not recruiting
Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System
This study looks at how safe and effective a new treatment called FARAPULSE is for atrial fibrillation. It collects real-world information about people treated with this system in hospitals to see how well it works and if it improves their quality of life.
Atrial FibrillationMalaysia - RecruitingPHASE3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
This study looks at the long-term safety of a new medicine, ianalumab, for people with lupus. It's for those who have already been in an earlier ianalumab study and continues to check how safe and well the medicine is tolerated over time.
Systemic Lupus ErythematosusMalaysia - Active not recruitingPHASE3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
This study compares a new drug, SB27, with an existing one, Keytruda, for advanced lung cancer. Both are given with chemotherapy. Researchers want to see if SB27 works as well as Keytruda for patients with non-small cell lung cancer that has spread.
Non-small Cell Lung Cancer Stage IVMalaysia - Not yet recruitingPHASE2
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
This study looks at a new combination treatment for advanced bowel cancer that has spread. It combines a new drug, VVD-133214, with an existing immunotherapy, pembrolizumab. The aim is to see if this combination works better than pembrolizumab alone for certain types of bowel cancer.
Colorectal AdenocarcinomaMalaysia - RecruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
Diffuse Large B-Cell LymphomaMalaysia - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
Colon AdenocarcinomaRectal AdenocarcinomaMalaysia - Active not recruitingPHASE3
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
This study is testing a new medicine called Mim8 for people with haemophilia A, including those with inhibitors. Mim8 aims to prevent bleeding episodes by helping blood clot. It's for people already in other Mim8 studies.
Haemophilia AHaemophilia A With InhibitorsMalaysia - RecruitingPHASE3
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This study is looking at a new medicine called Elecoglipron for people with certain types of heart failure. It compares Elecoglipron to a dummy medicine (placebo) to see if it helps improve heart health outcomes for adults already taking other heart failure medications, including dapagliflozin.
Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)Malaysia - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerMalaysia - Active not recruitingPHASE3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
This study, called ARTEMIS, is testing a new medicine called ziltivekimab for people who have had a heart attack. It aims to see if ziltivekimab can prevent future heart problems compared to a dummy medicine.
Cardiovascular RiskAcute Myocardial Infarction (AMI)Malaysia - RecruitingPHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This study looks at a new medicine called elecoglipron for people with long-term kidney disease. We want to see if it helps improve health compared to a dummy pill (placebo). Participants will also be taking existing kidney disease treatments like dapagliflozin. It's a large study, involving many people to get clear results.
Chronic Kidney DiseaseMalaysia - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal CancerMalaysia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseMalaysia - RecruitingPHASE2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is looking into a new medicine called Ianalumab for people in the UK with a specific type of scleroderma called diffuse cutaneous systemic sclerosis. It aims to see if the drug is safe and helps with symptoms, compared to a dummy treatment.
Diffuse Cutaneous Systemic SclerosisMalaysia - Recruiting
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
This study looks at how well new migraine medicines, called CGRP drugs, work in real life. It follows people already taking these medicines for two years to see their effects and how they manage their migraine.
MigraineEpisodic MigraineChronic Migraine, HeadacheMalaysia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerMalaysia - RecruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
Chronic Kidney DiseaseProteinuriaChildrenMalaysia - Active not recruitingPHASE3
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
This study looks at a new medicine called remibrutinib for chronic spontaneous urticaria (CSU), comparing it to a dummy treatment (placebo) and another existing medicine, omalizumab. It aims to see if remibrutinib is safe and helps reduce hives and itching in adults whose CSU isn't well controlled by usual allergy medicines.
Chronic Spontaneous UrticariaMalaysia - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
This study looks at a new drug, sacituzumab tirumotecan, for people with a type of lung cancer (non-small cell lung cancer) that has specific genetic changes and has worsened after previous treatments. It compares this new drug to a standard chemotherapy combination to see if it improves survival.
Non-small Cell Lung Cancer (NSCLC)Malaysia - Active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
Carcinoma, Renal CellMalaysia - Active not recruitingPHASE3
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
This study looks at a new weekly medicine, somapacitan, for children who need help growing. It compares it to Norditropin®, a daily medicine already used. The study includes children born small, or with Turner, Noonan syndrome, or unexplained short stature, over up to 5.5 years.
SGA, Turner Syndrome, Noonan Syndrome, ISSMalaysia - Active not recruitingPHASE4
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
This study offers ongoing access to ceritinib for patients already benefiting from it in another Novartis study. It's for people with ALK-positive cancers who, along with their doctor, believe continued treatment is helping them.
ALK Positive MalignanciesMalaysia - Active not recruitingPHASE1
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
This study compares a new medicine called GME751 to an existing treatment, Keytruda, for people with melanoma that has been removed by surgery. It checks if GME751 works similarly and is safe.
MelanomaMalaysia - RecruitingPHASE4
Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study
This study looks at how long people need antibiotics after heart surgery to prevent infections. We're comparing short courses (just during surgery) with longer ones (24 or 48 hours after) to see which works best and is safest for patients.
Surgical Site InfectionMalaysia - Active not recruitingPHASE3
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
This study is looking at a new medicine called guselkumab for people with psoriatic arthritis. It aims to see how well it reduces pain, swelling, and other symptoms compared to a dummy treatment, and if it helps improve their condition.
Arthritis, PsoriaticMalaysia - Active not recruitingPHASE3
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
This study is testing if a medicine called selexipag can help children aged 2-17 with a serious lung condition called pulmonary hypertension. It aims to see if adding selexipag to their usual treatment can slow down the disease compared to a dummy medicine.
Hypertension, PulmonaryMalaysia - Active not recruitingPHASE2
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
This study is testing a new medicine, Claseprubart, for adults with Multifocal Motor Neuropathy (MMN). We want to see if it's safe, how it works in the body, and if it can help improve symptoms. Participants will receive either the new medicine or a placebo.
Multifocal Motor NeuropathyMalaysia - RecruitingPHASE2
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
This study looks at a new medicine called luspatercept for people with a type of anaemia called alpha-thalassaemia. It aims to see if the medicine is safe and helps reduce the need for blood transfusions.
AnemiaMalaysia - Active not recruitingPHASE3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
This study looks at a new combination of treatments for a type of advanced lung cancer. It compares a drug called amivantamab plus standard chemotherapy to chemotherapy alone, to see if the combination works better at stopping the cancer from growing.
Carcinoma, Non-Small-Cell LungMalaysia - RecruitingPHASE3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
This study looks at a new medicine called BGB-43395 combined with letrozole for advanced breast cancer. It compares this new combination to standard treatments (other CDK4/6 inhibitors plus letrozole) for people who haven't had previous treatment for their advanced cancer.
HR+/HER2- Breast CancerMalaysia - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at two new drug combinations, amivantamab and lazertinib, compared to a standard drug, osimertinib, for people in the UK with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation).
Carcinoma, Non-Small-Cell LungMalaysia - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseMalaysia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
Early Breast CancerMalaysia - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCMalaysia - RecruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisMalaysia - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsMalaysia - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Malaysia - Active not recruitingPHASE3
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
This study is looking into a new drug, zipalertinib, for people with a certain type of lung cancer (NSCLC) in its early stages. It compares zipalertinib with standard chemotherapy to a dummy pill (placebo) with standard chemotherapy after surgery.
Lung CancerAdjuvantPost-surgicalEGFRMalaysia - RecruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
Non-Small Cell Lung Cancer (NSCLC)Malaysia - RecruitingPHASE3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This study looks at a new drug, Trastuzumab Deruxtecan, combined with an existing treatment, Bevacizumab, for a type of advanced ovarian cancer. It aims to see if this combination works better than Bevacizumab alone after initial chemotherapy.
Ovarian CancerMalaysia - RecruitingPHASE3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
This study is testing a new drug, Elacestrant, against standard hormone treatments for early breast cancer. It's for men and women whose cancer is ER-positive and HER2-negative, and has a high chance of coming back. The aim is to see if Elacestrant works better.
Breast CancerMalaysia - RecruitingPHASE2
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This study is testing a new medicine, WAL0921, for people with certain kidney conditions, like diabetic kidney disease or rare kidney problems. It aims to see if the medicine is safe and effective in helping your kidneys. Some people will get the medicine, and others a dummy treatment.
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change DiseasePrimary Immunoglobulin A NephropathyMalaysia - Active not recruitingPHASE3
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
This study is testing a new medicine called sibeprenlimab for a kidney disease called IgA nephropathy (IgAN). It aims to see if the medicine can reduce protein in the urine and protect kidney function over time, compared to a dummy medicine.
Immunoglobulin A NephropathyMalaysia - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisMalaysia - Active not recruitingPHASE3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
This study is looking at a new medicine called milvexian to see if it can help prevent another stroke in people who have recently had a mini-stroke or a type of stroke called an ischemic stroke.
Ischemic Stroke; Ischemic Attack, TransientMalaysia - Active not recruitingPHASE2
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
This study is checking if the benefits of bepirovirsen for Hepatitis B last over time. It's for people who previously took part in a bepirovirsen trial and showed good results. No new treatment is given in this follow-up study, just monitoring.
Hepatitis BMalaysia - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)Malaysia